Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases
8 Pages Posted: 18 Apr 2023
Date Written: April 17, 2023
This cross-sectional study compares Medicare & Medicaid spending on and beneficiaries of ultra-rare, rare, common, and non-orphan cancer drugs.
Funding Information: No funding was received for conducting this study.
Conflict of Interests: The authors declare that they have no conflicts of interest.
Keywords: orphan designation; cancer drug; healthcare expenditure; common orphans; rare orphans; ultra-rare orphans
JEL Classification: I1;I10;I13;I18
Suggested Citation: Suggested Citation